Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma
- 22 November 2011
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 12 (1) , 113-118
- https://doi.org/10.1517/14712598.2012.642359
Abstract
Introduction: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an at...Keywords
This publication has 17 references indexed in Scilit:
- Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthmaJournal of Allergy and Clinical Immunology, 2010
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJournal of Allergy and Clinical Immunology, 2010
- A review of treatment with mepolizumab, an anti–IL-5 mAb, in hypereosinophilic syndromes and asthmaJournal of Allergy and Clinical Immunology, 2010
- Mepolizumab for Prednisone-Dependent Asthma with Sputum EosinophiliaNew England Journal of Medicine, 2009
- Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levelsJournal of Allergy and Clinical Immunology, 2008
- Interleukin-5 Receptor Subunit Oligomerization and Rearrangement Revealed by Fluorescence Resonance Energy Transfer ImagingPublished by Elsevier ,2008
- Eosinophil trafficking in allergy and asthmaJournal of Allergy and Clinical Immunology, 2007
- IL-5 and IL-5 receptor in asthmaMemórias do Instituto Oswaldo Cruz, 1997
- A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific α chain and a β chain shared with the receptor for GM-CSFCell, 1991
- Characterization of the human IL-5 receptors on eosinophilsCellular Immunology, 1991